当归对乳腺癌患者安全吗?临床前综合证据回应质疑
该研究采用人乳腺癌细胞、原位荷瘤小鼠模型及患者肿瘤原代细胞,系统评估当归热水提取物对乳腺癌进展的影响。结果显示当归在体外和体内对乳腺癌的刺激作用并不明显,但在雌激素受体阳性乳腺癌患者中仍应谨慎使用。该临床前评估方法被证明可行。
要点
- 当归在临床前模型中未显示明显刺激乳腺癌生长。
- 雌激素受体阳性乳腺癌患者使用当归仍需谨慎。
- 临床前多模型评估可用于中药安全性评价。
核心结论
- 当归在体外和体内对乳腺癌的刺激作用并不明显,但在雌激素受体阳性乳腺癌患者中仍应谨慎使用。
研究设计与样本
- 研究采用人乳腺癌细胞、乳腺原位荷瘤小鼠模型以及患者肿瘤原代细胞,评估当归热水提取物对乳腺癌进展和癌细胞生长的影响。
主要发现
- 当归在体外和体内对乳腺癌的刺激作用并不明显。
临床怎么用
- 临床医生和中医师在雌激素受体阳性乳腺癌患者中使用当归时应保持谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Angelica sinensis (AS, Danggui) has long been regarded to stimulate breast cancer growth; hence, the use of AS in breast cancer patients remains a major concern for both patients and practitioners. Since safety studies of herbs would be unethical to carry out in patients, the present study aimed to investigate the potential unsafe effects of AS in a systematic pre-clinical approach. Human breast cancer cells, breast orthotopic tumor-bearing mouse models, as well as primary breast cancer cells from patients' tumors were used to evaluate the effect of AS hot water extract on the progression of breast tumors and/or growth of breast cancer cells. We showed that AS is not that stimulatory in breast cancer both in vitro and in vivo, though AS should still be used with caution in estrogen receptor-positive breast cancer patients. This novel approach of applying breast cancer cell lines, xenograft, and syngeneic tumors models, as well as primary breast cancer cells from patients' tumors in Chinese medicines safety evaluation was proven feasible. Our finding is important information for patients, Chinese medicine practitioners, and clinicians on the safety use of AS in breast cancer, which will affect future clinical practice.
引用
- Yue GG, Wong LS, Leung HW, et al. Is Danggui Safe to be Taken by Breast Cancer Patients?-A Skepticism Finally Answered by Comprehensive Preclinical Evidence. Front Pharmacol. 2019. PMID: 31293425. doi:10.3389/fphar.2019.00706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。